Oxaliplatin immune-induced syndrome (OIIS) is an uncommon, potentially life-threatening,
side effect associated with oxaliplatin-based chemotherapy. The present study reports 5 …

Thrombotic microangiopathies (TMAs) represent a complex interaction of endothelial and
podocyte biology, nephron physiology, complement genetics, and oncologic therapies with …

Thrombocytopenia developing in the course of chemotherapy for malignant disease is
usually attributed to drug‐induced marrow suppression and/or marrow replacement by …

An update on drug-induced immune hemolytic anemia Blog English EnglishGerman Sciendo
Logo Login Publish with us Subjects Architecture and DesignArtsBusiness and …

BACKGROUND: Oxaliplatin, a third‐generation platinum compound, has been implicated in
isolated cases of immune hemolytic anemia and/or immune thrombocytopenia. The first …

BACKGROUND: Two patients were suspected of having immune hemolytic anemia (IHA)
due to oxaliplatin. A related drug, cisplatin, is known to cause nonimmunologic protein …

Abstract Oxaliplatin (1, 2-diamminocyclohexaneoxalato-platinum) is a novel platin analog,
which is widely used in gastrointestinal malignancies. Platinum analogs damage cellular …

We report a 59-year-old woman diagnosed with metastasic colorectal cancer who
developed immune hemolytic anemia during FOLFOX chemotherapy (oxaliplatin/leucovorin …

Background Oxaliplatin, a third‐generation platinum derivative is commonly used in
combination treatment of metastatic colorectal cancer. Since 2008, it is the second most …

Background Oxaliplatin is a platinum derivative, which is used in the treatment of colorectal
cancer. A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions …